Wildtype σ1 receptor and the receptor agonist improve ALS-associated mutation-induced insolubility and toxicity

J Biol Chem. 2020 Dec 18;295(51):17573-17587. doi: 10.1074/jbc.RA120.015012.

Abstract

Genetic mutations related to ALS, a progressive neurological disease, have been discovered in the gene encoding σ-1 receptor (σ1R). We previously reported that σ1RE102Q elicits toxicity in cells. The σ1R forms oligomeric states that are regulated by ligands. Nevertheless, little is known about the effect of ALS-related mutations on oligomer formation. Here, we transfected NSC-34 cells, a motor neuronal cell line, and HEK293T cells with σ1R-mCherry (mCh), σ1RE102Q-mCh, or nontagged forms to investigate detergent solubility and subcellular distribution using immunocytochemistry and fluorescence recovery after photobleaching. The oligomeric state was determined using crosslinking procedure. σ1Rs were soluble to detergents, whereas the mutants accumulated in the insoluble fraction. Within the soluble fraction, peak distribution of mutants appeared in higher sucrose density fractions. Mutants formed intracellular aggregates that were co-stained with p62, ubiquitin, and phosphorylated pancreatic eukaryotic translation initiation factor-2-α kinase in NSC-34 cells but not in HEK293T cells. The aggregates had significantly lower recovery in fluorescence recovery after photobleaching. Acute treatment with σ1R agonist SA4503 failed to improve recovery, whereas prolonged treatment for 48 h significantly decreased σ1RE102Q-mCh insolubility and inhibited apoptosis. Whereas σ1R-mCh formed monomers and dimers, σ1RE102Q-mCh also formed trimers and tetramers. SA4503 reduced accumulation of the four types in the insoluble fraction and increased monomers in the soluble fraction. The σ1RE102Q insolubility was diminished by σ1R-mCh co-expression. These results suggest that the agonist and WT σ1R modify the detergent insolubility, toxicity, and oligomeric state of σ1RE102Q, which may lead to promising new treatments for σ1R-related ALS.

Keywords: amyotrophic lateral sclerosis (ALS) (Lou Gehrig disease); cell death; fluorescence recovery after photobleaching (FRAP); oligomerization; protein aggregation; subcellular fractionation; σ receptor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis / genetics
  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / pathology*
  • Apoptosis / drug effects
  • Cell Line
  • Endoplasmic Reticulum Stress
  • Fluorescence Recovery After Photobleaching
  • Humans
  • Luminescent Proteins / genetics
  • Luminescent Proteins / metabolism
  • Mutagenesis, Site-Directed
  • Piperazines / pharmacology
  • Protein Aggregates / drug effects
  • Protein Multimerization / drug effects
  • Receptors, sigma / agonists
  • Receptors, sigma / genetics
  • Receptors, sigma / metabolism*
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / genetics
  • Red Fluorescent Protein
  • Sigma-1 Receptor
  • Solubility

Substances

  • Luminescent Proteins
  • Piperazines
  • Protein Aggregates
  • Receptors, sigma
  • Recombinant Fusion Proteins
  • SA 4503